Lexeo Therapeutics Statistics
Total Valuation
LXEO has a market cap or net worth of $207.65 million. The enterprise value is $61.04 million.
Important Dates
The next estimated earnings date is Tuesday, December 31, 2024, after market close.
| Earnings Date | Dec 31, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
LXEO has 33.07 million shares outstanding. The number of shares has increased by 1,601.39% in one year.
| Current Share Class | 33.07M |
| Shares Outstanding | 33.07M |
| Shares Change (YoY) | +1,601.39% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 4.47% |
| Owned by Institutions (%) | 65.53% |
| Float | 18.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.49 |
| P/TBV Ratio | 1.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.95, with a Debt / Equity ratio of 0.07.
| Current Ratio | 5.95 |
| Quick Ratio | 5.86 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -594.64 |
Financial Efficiency
Return on equity (ROE) is -107.21% and return on invested capital (ROIC) is -62.02%.
| Return on Equity (ROE) | -107.21% |
| Return on Assets (ROA) | -51.05% |
| Return on Capital (ROIC) | -62.02% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.49M |
| Employee Count | 58 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.03% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -54.03% |
| 50-Day Moving Average | 7.92 |
| 200-Day Moving Average | 11.86 |
| Relative Strength Index (RSI) | 39.89 |
| Average Volume (20 Days) | 274,780 |
Short Selling Information
The latest short interest is 2.20 million, so 6.66% of the outstanding shares have been sold short.
| Short Interest | 2.20M |
| Short Previous Month | 2.49M |
| Short % of Shares Out | 6.66% |
| Short % of Float | 11.82% |
| Short Ratio (days to cover) | 6.55 |
Income Statement
| Revenue | n/a |
| Gross Profit | -63.94M |
| Operating Income | -93.36M |
| Pretax Income | -69.42M |
| Net Income | -86.60M |
| EBITDA | -92.73M |
| EBIT | -93.36M |
| Earnings Per Share (EPS) | -$3.13 |
Full Income StatementBalance Sheet
The company has $157.02 million in cash and $10.40 million in debt, giving a net cash position of $146.62 million or $4.43 per share.
| Cash & Cash Equivalents | 157.02M |
| Total Debt | 10.40M |
| Net Cash | 146.62M |
| Net Cash Per Share | $4.43 |
| Equity (Book Value) | 139.33M |
| Book Value Per Share | 4.21 |
| Working Capital | 132.64M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$66.81 million and capital expenditures -$554,000, giving a free cash flow of -$67.36 million.
| Operating Cash Flow | -66.81M |
| Capital Expenditures | -554,000 |
| Free Cash Flow | -67.36M |
| FCF Per Share | -$2.04 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |